Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Mirati Therapeutics (MRTX)

Mirati Therapeutics (MRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,114,358
  • Shares Outstanding, K 39,436
  • Annual Sales, $ 12,930 K
  • Annual Income, $ -98,420 K
  • 60-Month Beta 2.05
  • Price/Sales 314.79
  • Price/Cash Flow N/A
  • Price/Book 8.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -1.50
  • Number of Estimates 7
  • High Estimate -1.35
  • Low Estimate -1.71
  • Prior Year -0.87
  • Growth Rate Est. (year over year) -72.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
74.00 +40.99%
on 10/21/19
106.43 -1.97%
on 11/12/19
+27.40 (+35.62%)
since 10/11/19
3-Month
69.50 +50.12%
on 10/03/19
106.43 -1.97%
on 11/12/19
+13.36 (+14.69%)
since 08/12/19
52-Week
34.39 +203.37%
on 12/24/18
111.99 -6.84%
on 07/31/19
+65.92 (+171.62%)
since 11/12/18

Most Recent Stories

More News
Watch for Mirati Therapeut to Potentially Pullback After Gaining 33.10% Yesterday

Mirati Therapeut (NASDAQ:MRTX) traded in a range yesterday that spanned from a low of $102.43 to a high of $106.31. Yesterday, the shares gained 33.1%, which took the trading range above the 3-day high...

MRTX : 104.22 (-0.11%)
Mirati Therapeutics Presents Data From Ongoing Clinical Trials Of Sitravatinib In Combination With Nivolumab At The SITC 34th Annual Meeting

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced the presentation of initial data from its ongoing Phase 2 clinical trial of sitravatinib in combination...

MRTX : 104.22 (-0.11%)
Noteworthy Tuesday Option Activity: MRTX, R, GPRE

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Mirati Therapeutics Inc , where a total volume of 5,862 contracts has been traded thus...

MRTX : 104.22 (-0.11%)
R : 52.62 (-1.55%)
Mirati (MRTX) Reports Q3 Loss, Tops Revenue Estimates

Mirati (MRTX) delivered earnings and revenue surprises of -8.66% and 97.60%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

MRTX : 104.22 (-0.11%)
Mirati: 3Q Earnings Snapshot

SAN DIEGO (AP) _ Mirati Therapeutics Inc. (MRTX) on Monday reported a loss of $54.3 million in its third quarter.

MRTX : 104.22 (-0.11%)
Mirati Therapeutics Reports Third Quarter 2019 Financial Results

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter ended September 30, 2019.

MRTX : 104.22 (-0.11%)
Mirati Therapeutics Presents First Clinical Data Of Phase 1/2 Trial Of MRTX849 At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced the first clinical results from its Phase 1/2 trial evaluating MRTX849, an investigational KRAS G12C...

MRTX : 104.22 (-0.11%)
Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (AMAG , MRTX, ARWR, AIMT , BMRN )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

AMAG : 9.05 (-1.74%)
MRTX : 104.22 (-0.11%)
ARWR : 44.65 (-1.39%)
Mirati Therapeut Set to Possibly Pullback After Yesterday's Rally of 2.94%

Mirati Therapeut (NASDAQ:MRTX) traded in a range yesterday that spanned from a low of $75.95 to a high of $83.38. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high...

MRTX : 104.22 (-0.11%)
Shares of MRTX Down 5.7% Since Downtrend Call on Shares

SmarTrend identified a Downtrend for Mirati Therapeut (NASDAQ:MRTX) on September 30th, 2019 at $80.63. In approximately 3 weeks, Mirati Therapeut has returned 5.66% as of today's recent price of $76.06....

MRTX : 104.22 (-0.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade MRTX with:

Business Summary

Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel therapeutics for the treatment of cancer. Mirati Therapeutics, Inc., formerly known as MethylGene Inc., is based in Montreal, Canada.

See More

Key Turning Points

2nd Resistance Point 108.39
1st Resistance Point 106.36
Last Price 104.22
1st Support Level 102.37
2nd Support Level 100.41

See More

52-Week High 111.99
Last Price 104.22
Fibonacci 61.8% 82.35
Fibonacci 50% 73.19
Fibonacci 38.2% 64.03
52-Week Low 34.39

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar